A randomized phase 2 trial of Irinotecan/Paclitaxel versus Irinotecan/Gemcitabine in patient with stage IIIB/IV non small cell lung cancer.

Authors
Category Primary study
JournalJapan Primary Registry Network
Year 2005
INTERVENTION: Intervention name : Irinotecan (CPT‐11) Dosage And administration of the intervention : Injection CONDITION: Non Small Cell Lung cancer(NSCLC) PRIMARY OUTCOME: Best overall response INCLUSION CRITERIA: Histologically confirmed NSCLC Neither prior chemotherapy nor prior radiotherapy Age between 20 and 74 years old ECOG Performance Status: 0‐1
Epistemonikos ID: 8789f42c082ea10d460dd00c211556ee9c9b7175
First added on: Aug 21, 2024